Alnylam Pharmaceuticals Stock Analysis

Alnylam Stock Analysis Notes

About 95.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 3.52. Alnylam Pharmaceuticals had not issued any dividends in recent years. Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1665 people. For more info on Alnylam Pharmaceuticals please contact John Maraganore at 617 551 8200 or go to https://www.alnylam.com.

Alnylam Pharmaceuticals Investment Alerts

Alnylam Pharmaceuticals Upcoming and Recent Events

Alnylam Largest EPS Surprises

View All Earnings Estimates

Alnylam Stock Institutional Investors

Note, although Alnylam Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Alnylam Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 18.47 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alnylam Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Alnylam Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Alnylam Profitablity

The company has Profit Margin (PM) of (0.24) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.26) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.26.

Management Efficiency

Alnylam Pharmaceuticals has return on total asset (ROA) of (0.0478) % which means that it has lost $0.0478 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.0066) %, meaning that it created substantial loss on money invested by shareholders. Alnylam Pharmaceuticals' management efficiency ratios could be used to measure how well Alnylam Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 2.10 in 2024, whereas Return On Tangible Assets are likely to drop (0.15) in 2024. At this time, Alnylam Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 889.5 M in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (3.4 B).

Technical Drivers

As of the 25th of April, Alnylam Pharmaceuticals shows the Standard Deviation of 2.14, mean deviation of 1.41, and Risk Adjusted Performance of (0.09). Alnylam Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate thirteen technical drivers for Alnylam Pharmaceuticals, which can be compared to its peers. Please confirm Alnylam Pharmaceuticals standard deviation and potential upside to decide if Alnylam Pharmaceuticals is priced correctly, providing market reflects its regular price of 143.8 per share. Given that Alnylam Pharmaceuticals has information ratio of (0.20), we suggest you to validate Alnylam Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Alnylam Pharmaceuticals Price Movement Analysis

Alnylam Pharmaceuticals Insider Trading Activities

Alnylam Pharmaceuticals Predictive Daily Indicators

Alnylam Pharmaceuticals Corporate Filings

Alnylam Pharmaceuticals Forecast Models

Alnylam Pharmaceuticals' time-series forecasting models are one of many Alnylam Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Alnylam Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Alnylam Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Alnylam shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Alnylam Pharmaceuticals. By using and applying Alnylam Stock analysis, traders can create a robust methodology for identifying Alnylam entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Alnylam analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Alnylam analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Alnylam Pharmaceuticals stock analysis indicators help investors evaluate how Alnylam Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Alnylam Pharmaceuticals shares will generate the highest return on investment. By understating and applying Alnylam Pharmaceuticals stock analysis, traders can identify Alnylam Pharmaceuticals position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Is Alnylam Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alnylam Pharmaceuticals. If investors know Alnylam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alnylam Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Alnylam Pharmaceuticals is measured differently than its book value, which is the value of Alnylam that is recorded on the company's balance sheet. Investors also form their own opinion of Alnylam Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Alnylam Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alnylam Pharmaceuticals' market value can be influenced by many factors that don't directly affect Alnylam Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alnylam Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alnylam Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alnylam Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.